Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in kidney cancer
- Trial result
Kidney cancer
Chemo + checkpoint inhibitor (PD-1/PD-L1) extends OS vs chemo alone in metastatic head & neck PD-NEC (NCDB)
In this NCDB real‑world cohort (2018–2023) of metastatic poorly differentiated head and neck neuroendocrine carcinomas (HN‑NECs; n=275; survival data available for 227), systemic chemotherapy (typical backbone in…
- New trial Spotlight
Kidney cancer
Phase 3 belzutifan HIF-2α inhibitor + zanzalintinib MET/VEGFR TKI vs cabozantinib
Merck Sharp & Dohme (MSD) is running LITESPARK-033 (MK-6482-033), a Phase 3, randomized, open-label, multicenter study in recurrent advanced clear cell RCC after prior adjuvant anti–PD-1/PD-L1 therapy. Participants…
NCT07227402 Registrational - Trial result Spotlight
Kidney cancer
SABR (26Gy×1 or 42Gy/3fx) Delivers 100% 7-Year Local Control in Inoperable Primary RCC (FASTRACK II)
Stereotactic ablative body radiotherapy (SABR; high-dose, image-guided hypofractionated RT) was tested in FASTRACK II (TROG 15.03), a multicentre, non-randomised Phase 2 study in medically inoperable/high-risk or…
- New trial
Kidney cancer
Phase 2 zanzalintinib (XL092) multi-kinase VEGFR2/MET/AXL inhibitor + MO-03 microbiome immunomodulator
This single-arm Phase 2 study at City of Hope tests zanzalintinib (XL092) plus MO-03 (CBM588; *Clostridium butyricum* strain M588) in metastatic clear-cell renal cell carcinoma that has progressed after…
NCT07578025 Exploratory - New trial Spotlight
Kidney cancer
Phase 1 LNK001 dual ENPP3/CAIX AND-gated CAR T in ccRCC
MD Anderson Cancer Center is running a Phase 1, two-part (dose escalation then expansion) study testing LNK001, an autologous CAR T-cell therapy engineered as an AND-gate that requires dual recognition of ENPP3 and…
NCT07564232 First-in-human - Trial result
Kidney cancer
Pembrolizumab (PD-1) + radiotherapy MDT trends toward longer PFS in oligometastatic ccRCC
Radiotherapy-based metastasis-directed therapy (MDT) with or without pembrolizumab maintenance was compared in a pooled, exploratory analysis of two prospective single-arm Phase 2 trials (MDT+ICI: NCT02855203; MDT…
NCT02855203 - New trial
Kidney cancer
Phase 1b/2 zanzalintinib (c-MET/VEGFR TKI) + belzutifan (HIF-2α) in recurrent ccRCC during/after adjuvant anti-PD-(L)1
Within KEYMAKER-U03 (Merck), this doublet targets angiogenesis (VEGFR/MET) plus hypoxia signaling (HIF-2α) in patients recurring on/after adjuvant IO. Frontline RCC has moved to IO+TKI, and belzutifan has traction…
NCT07049926 Exploratory - New trial
Kidney cancer
Phase I nivolumab/ipilimumab ± EXL01 live biotherapeutic in mRCC
City of Hope evaluates whether gut-microbiome modulation (EXL01 from Exeliom Biosciences) augments response to the established nivo/ipi doublet (BMS). Many patients fail to achieve deep or durable benefit on IO;…
NCT07128680 Exploratory - New trial
Kidney cancer
Phase 2 Sasanlimab PD-1 mAb trial for advanced renal cell carcinoma
This Phase 2 trial evaluates the safety and efficacy of a combination regimen in advanced clear cell or translocation renal cell carcinoma. Participants receive sasanlimab (a PD-1-targeted monoclonal antibody),…
NCT07123090 Exploratory - New trial
Kidney cancer
Phase 1 pilot: 89Zr-Girentuximab, anti-CAIX imaging agent for renal cell carcinoma PET evaluation.
This study evaluates whether PET imaging with 89Zr-Girentuximab, a CAIX-targeted agent, can detect residual or recurrent ccRCC in patients. In one group, participants undergo a PET scan post-injection, while the…
NCT07077083 Exploratory - New trial Spotlight
Kidney cancer
Phase 1 study of 111In-XYIMSR-01 radiotracer for clear cell renal cell carcinoma detection.
An early-phase open-label study at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins evaluates the safety and tumor-targeting performance of 111In-XYIMSR-01 via SPECT/CT in participants with metastatic clear…
NCT07062549 First-in-human - New trial
Kidney cancer
Phase II trial: CBM588 (microbiome modulator) with pembrolizumab (PD-1 inhibitor)
This Phase II study at City of Hope Medical Center evaluates the addition of probiotic CBM588 to pembrolizumab versus pembrolizumab alone as adjuvant therapy in resected high-risk renal cell carcinoma. Patients…
NCT07037004 Exploratory - New trial
Kidney cancer
Phase II Zanzalintinib cMET/VEGFR inhibitor for metastatic clear cell renal cell carcinoma
This single-institution phase II trial evaluates zanzalintinib, a small molecule cMET/VEGFR inhibitor given orally in 28-day cycles, combined with an investigator-chosen bisphosphonate for bone metastases in patients…
NCT07043608 Exploratory - Trial result
Kidney cancer
GAS6/AXL-Blocking Batiraxcept + Cabozantinib Yields 43% ORR in Heavily Pretreated ccRCC
Batiraxcept—a recombinant Fc fusion that soaks up GAS6 to shut down AXL signaling—was paired with cabozantinib in the phase 1b/2 NCT04300140 study. Among 51 previously treated clear-cell RCC patients given the…
NCT04300140 - Trial result
Kidney cancer
VEGF-Blocker Bevacizumab + EGFR-TKI Erlotinib Delivers 72% ORR and 21-mo mPFS in Hereditary Papillary RCC
Bevacizumab (anti-VEGF antibody) plus erlotinib (EGFR tyrosine-kinase inhibitor) was tested in an open-label Phase 2 study (NCT01130519) enrolling 43 patients with fumarate-hydratase–mutated hereditary leiomyomatosis…
NCT01130519 - Trial result
Kidney cancer
Zanzalintinib (VEGFR/MET) + Nivolumab Yields 63% ORR in Front-Line ccRCC; Triplet With Relatlimab Lags
Zanzalintinib (zanza; XL092) is an oral multi-kinase TKI targeting VEGFR, MET, and TAM receptors; in the Phase 1b STELLAR-002 expansion (NCT05176483), 40 untreated metastatic Clear Cell Renal Carcinoma (ccRCC)…
NCT05176483 - Trial result
Kidney cancer
Cabozantinib Alone Matches Cabo + Atezolizumab After 1L IO Combos in RCC with 10-month mPFS
Cabozantinib, an oral VEGFR/MET/AXL TKI, monotherapy was compared with cabozantinib + atezolizumab (anti-PD-L1 antibody) in a CONTACT-03 (NCT04338269) subgroup of 236 advanced renal-cell carcinoma patients whose…
NCT04338269 - Trial result
Kidney cancer
Casdatifan (HIF-2α) + cabozantinib logs 41% ORR in previously treated clear-cell RCC
Casdatifan, an oral hypoxia-inducible-factor-2α inhibitor, combined with cabozantinib (VEGFR-TKI) in the Phase 1 ARC-20 expansion (NCT05536141). Twenty-seven adults with IO-exposed ± VEGFR-TKI clear-cell RCC received…
NCT05536141 - New trial
Kidney cancer
Phase I/II Trial of Bicalutamide, an Androgen Receptor Inhibitor in Renal Cancer
This open-label study evaluates the safety and efficacy of bicalutamide plus sunitinib administered in cycles among advanced renal cell carcinoma patients with progression after prior receptor tyrosine kinase…
NCT06222593 - New trial
Kidney cancer
LASER - Phase 2 Trial of 177Lu-PSMA-617 in PSMA-Positive ccRCC
Dana-Farber is evaluating 177Lu-PSMA-617—a radioligand therapy delivering beta radiation via lutetium-177 vipivotide tetraxetan—as a systemic treatment in PSMA-positive advanced/metastatic clear cell renal cell…
NCT06964958 - New trial
Kidney cancer
Phase II Study of Total MPDT in Metastatic Clear Cell RCC
This open-label phase II trial evaluates total consolidative metastasis-and-primary directed therapy (MPDT) in metastatic clear cell RCC patients with partial response or stable disease after at least 6 months of…
NCT06770855 - New trial
Kidney cancer
Randomized Phase II Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Columbia University Medical Center is testing XL092 alone versus XL092 combined with nivolumab in patients with advanced clear cell RCC who have progressed on adjuvant anti-PD-1/PD-L1 therapy, with treatment given in…
NCT06863311 - New trial
Kidney cancer
Risk-Adapted Treatment Trial for Unilateral Favorable Histology Wilms Tumors
The Children's Oncology Group is conducting a phase III trial that tailors treatment intensity for pediatric unilateral FHWT based on tumor histology, biology, and response to therapy. This comprehensive study…
NCT06401330 - New trial
Kidney cancer
Phase II Study of Ivonescimab in Advanced Clear Cell RCC
M.D. Anderson Cancer Center in Houston is evaluating ivonescimab—a PD-1 and VEGF bispecific antibody—administered IV every three weeks in patients with advanced clear cell RCC who have progressed on prior…
NCT06940518
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.